rss
Gut 57:1524-1529 doi:10.1136/gut.2008.151415
  • Inflammatory bowel disease

Crohn’s disease: factors associated with exposure to high levels of diagnostic radiation

  1. A N Desmond1,
  2. K O’Regan2,
  3. C Curran1,
  4. S McWilliams1,
  5. T Fitzgerald3,
  6. M M Maher2,
  7. F Shanahan1
  1. 1
    Department of Medicine, Alimentary Pharmabiotic Centre, National University of Ireland, Cork, Ireland
  2. 2
    Department of Radiology, Cork University Hospital, Cork, Ireland
  3. 3
    Department of Epidemiology, Alimentary Pharmabiotic Centre, National University of Ireland, Cork, Ireland
  1. Professor F Shanahan, Department of Medicine, Alimentary Pharmabiotic Centre, National University of Ireland, Cork, Ireland; f.shanahan{at}ucc.ie
  • Revised 9 April 2008
  • Accepted 15 April 2008
  • Published Online First 28 April 2008

Abstract

Aims: Exposure to diagnostic radiation may be associated with increased risk of malignancy. The aims of this study were to (1) examine patterns of use of imaging in Crohn’s disease; (2) quantify the cumulative effective dose (CED) of diagnostic radiation received by patients; and (3) identify patients at greatest risk of exposure to high levels of diagnostic radiation.

Methods: 409 patients with Crohn’s disease were identified at a tertiary centre. CED was calculated retrospectively from imaging performed between July 1992 and June 2007. High exposure was defined as CED>75 mSv, an exposure level which has been reported to increase cancer mortality by 7.3%. Complete data were available for 399 patients. 45 were excluded (20 attended outside the study period, 25 were primarily managed at other centres).

Results: Use of computed tomography increased significantly and accounted for 77.2% of diagnostic radiation. Mean CED was 36.1 mSv and exceeded 75 mSv in 15.5% of patients. Factors associated with high cumulative exposure were: age <17 years at diagnosis (hazard ratio 2.1, confidence interval (CI) 1.1 to 4.1), upper gastrointestinal tract disease (odds ratio (OR) 2.4, CI 1.2 to 4.9), penetrating disease (OR 2.0, CI 1.0 to 3.9) and requirement for intravenous steroids (OR 3.7, CI 2.0 to 6.6); infliximab (OR 2.3, CI 1.2 to 4.4); or multiple (>1) surgeries (OR 2.7, CI 1.4 to 5.4).

Conclusions: Identifiable subsets of patients with Crohn’s disease are at risk of exposure to significant amounts of diagnostic radiation. Given the background risk of neoplasia and exposure to potentially synergistic agents such as purine analogues and other immune modulators, specialist centres should develop low-radiation imaging protocols.

Footnotes

  • Funding: The authors are supported in part by Science Foundation Ireland, by the Health Research Board of Ireland and by the European Union.

  • Competing interests: None.

  • Ethics approval: Study approval was granted from the combined university and hospitals research ethics committee on 5 March 2006.